The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency

Irina V. Gribkova, Elena N. Lipets, Irina G. Rekhtina, Alex I. Bernakevich, Dorzho B. Ayusheev, Ruzanna A. Ovsepyan, Fazoil I. Ataullakhanov, & Elena I. Sinauridze

A new oral anticoagulant, dabigatran etexilate (DE, a prodrug of direct thrombin inhibitor (DTI) dabigatran), has been used clinically to prevent thrombosis. The assessment of dabigatran efficiency is necessary in some clinical cases, such as renal insufficiency, risk of bleeding, and drug interactions. However, a specific thrombin generation test (TGT) that is one of the most informative and sensitive to anticoagulant therapy (calibrated automated thrombinography (CAT)) shows a paradoxical increase of test parameters, such as endogenous thrombin potential (ETP) and peak thrombin, in patients receiving DE. The paradoxical behaviour of ETP and peak thrombin in these patients in the presence of DTIs is mostly caused by a decrease in the activity of thrombin in the α2-macroglobulin-thrombin complex that is used as a calibrator in CAT. For a correct estimation of the TGT parameters in patient’s plasma containing DTIs we proposed to use our previously described alternative calibration method that is based on the measurement of the fluorescence signal of a well-known concentration of the reaction product (7-amino-4-methylcoumarin). In this study, the validity of such approach was demonstrated in an ex vivo study in patients with knee replacement and two special patients with multiple myeloma, who received DE for thrombosis prophylaxis.

Currently, many preparations (heparins, vitamin K antagonists (VKAs), new oral anticoagulants) are used clinically to prevent thrombosis. Dabigatran etexilate (DE), a prodrug of the low molecular weight direct thrombin inhibitor dabigatran, has become increasingly popular. It is a new type oral anticoagulant. Advantage of this preparation compared to the VKAs, which have been the only type of oral anticoagulants until recently, is that it rapidly and directly target thrombin once formed and in contrast to VKAs does not interfere in the synthesis of vitamin K dependent coagulation factors. In addition, dabigatran may show a lower number of food and drug interactions. Moreover, dabigatran has a predictable pharmacokinetic profile and wide therapeutic-window, allowing for a fixed-dose regimen without the need for routine coagulation monitoring. However it has recently become increasingly clear that there are some clinical situations (renal insufficiency, risk of bleeding, and drug interactions) in which clinicians will need to make an assessment of the anticoagulant status of a patient receiving DE. It may even be vitally important.

Many studies have been dedicated to the possibility of an assessment of dabigatran efficiency using different laboratory tests. Not all the methods in use are appropriate for this task. Thrombin time (TT) can produce quantitative results only for low concentrations, as it is an over-sensitive test. The activated partial thromboplastin time (APTT) can only give an approximation of dabigatran activity at low concentrations but is not linear.
at dabigatran concentrations used clinically^{18,19,21,23}. International normalized ratio (or prothrombin time) have low sensitivity to DTIs^{18,19,21,23}.

Hemoclot Thrombin Inhibitor (HTI) (or dilute TT) may be a good test for the assessment of dabigatran efficiency. HTI showed excellent linear correlation at all doses^{11,16,18}. But it is not a global test, i.e. it is suitable to measure dabigatran concentrations but it cannot show the status of the coagulation system as the whole. In particular, it does not show reversal of dabigatran action by prothrombin complex concentrate administration^{24}. The global coagulation test of thrombin generation (TGT) developed and modified by H.C. Hemker (calibrated automated thrombinography, CAT)^{25} is a sensitive method for an assessment of the anticoagulant therapy, reflecting most if not all of coagulation system’s functions^{26–29}. This test determines the kinetics of the appearance of active thrombin in plasma after the activation of coagulation. The basic TGT parameters are: endogenous thrombin potential (ETP)—the sum amount of active thrombin which was present in the system over entire time of experiment (area under the thrombin generation curve), maximal thrombin concentration in the sample (peak thrombin), time to reach this maximal concentration (tmax), and lag-time before the beginning of accelerated thrombin production (t-lag), which is by convention determined as the time before the thrombin concentration in the sample reaches 10 nM. In the presence of anticoagulants, the first two parameters decrease, while tmax and t-lag increase.

In spite of the high sensitivity of TGT to the presence of different anticoagulants, the capabilities of this test in the assessment of DE application in vivo are not evident^{6}. The analysis of DE application for the prophylaxis of thrombosis in patients after hip or knee replacement in one study^{30} showed a paradoxical increase of ETP and peak thrombin (i.e. an apparent enhancement of thrombin generation) and simultaneously the expected change (prolongation) of two other test parameters tmax and t-lag (i.e. initiation of inhibition of thrombin generation). Similar results were recently obtained in another study in patients following orthopedic surgery and in patients with atrial fibrillation^{41}. Thus, the application of TGT in the presence of some anticoagulants is complicated and requires additional study^{8}.

The reasons for the irregular behavior of some TGT parameters in CAT in the presence of dabigatran are not well defined. In course of coagulation along with other reactions thrombin binds with $\alpha_2$-macroglobulin. Thrombin in this complex loses its capacity to interact with fibrinogen, but not with the low molecular weight substrates. In this complex it cannot be subjected to high molecular weight anticoagulants like heparins, making CAT an excellent method for monitoring them. However, dabigatran is a low molecular weight compound, and it can interact with free thrombin as well as with thrombin in the $\alpha_2$-macroglobulin-thrombin complex ($\alpha_2$MT). Wagenvoord et al.^{32} suggested that spuriously increased values of ETP and peak thrombin could be a consequence of the incorrect algorithm (for dabigatran samples) that is used in CAT to subtract $\alpha_2$MT activity from the total amidolytic activity in the experimental wells. On the other hand, dabigatran will also inhibit $\alpha_2$MT that is used as calibrator reagent in CAT and that is added to calibrator wells containing patient plasma as well. Dabigatran in the calibrator wells will decrease the value of the calibration signal and as a consequence thrombin values are calculated that are erroneously too high. As an alternative calibration approach that allows the measurement of TGT in patients receiving DE, we propose the use of a solution of 7-amino-4-methylcoumarin (AMC) in a well-defined concentration as a calibration standard. AMC is the fluorescent product of the hydrolysis reaction of the fluorogenic substrate used in CAT. Recently we successfully used the proposed method in vitro to examine a number of new DTIs^{33}. Aim of the present study is to explore whether this modified calibration protocol is applicable for the measurement of thrombin generation in samples from dabigatran-treated individuals.

**Results**

**Effect of DTIs on the activity of the thrombin calibrator used in CAT.** To determine the effect of DTIs on the activity of ThrCal used in CAT the rates of thrombin-specific substrate hydrolysis in the presence of a constant ThrCal concentration and different concentrations of two DTIs (dabigatran or 19 s) were measured both in buffer solution and plasma. Chromogenic substrate was used in buffer, whereas the fluorogenic substrate, commonly applied in CAT, was used in plasma. Different sets of plasma samples were used in each type of experiments. The results are shown in Fig. 1.

It is clear that in buffer solution, both dabigatran (Fig. 1a) and 19 s (Fig. 1b) inhibit the rate of chromogenic substrate hydrolysis by ThrCal in a concentration-dependent manner. The averaged values of the inhibition of the substrate hydrolysis rate (in %) for different concentrations of thrombin inhibitors are presented (mean ± SD, n = 5). Similarly, dabigatran and 19 s inhibit the accumulation of fluorescent product of thrombin-specific fluorogenic substrate hydrolysis by ThrCal in plasma. Dependencies of inhibition of AMC accumulation on the concentrations of DTIs in plasma are presented in Fig. 1c,d.

**Effect of DTIs on the fluorescence of AMC.** To eliminate the influence of DTIs on ThrCal activity (used in CAT for calibration), the calibration of fluorescent signals was performed by measuring the fluorescence of a well-defined concentration of hydrolysis product (AMC). The fluorescence of a constant concentration of AMC (8 μM) in the presence of different concentrations of these inhibitors was measured in the plasma of 5 donors (different for each inhibitor), and the fluorescence values for 1 μM of AMC were calculated. All the measurements were carried out in the presence of a constant concentration of fluorogenic substrate (400 μM) to emulate the conditions of TGT. The value of 1 μM AMC fluorescence (for each plasma sample) did not change in the presence of DTIs. It amounted to 723 ± 14, and 719 ± 26 arbitrary units (arb. un.) for dabigatran and 19 s, respectively, in the range of concentrations of dabigatran up to 1.6 μM, or 19 s up to 6.4 μM. No significant difference was observed between these values for both inhibitors (ANOVA, P > 0.05). This value was defined as the calibration value for the calculation of real AMC concentrations in plasma for each time point.
Parameters of TGT (method CAT) in the presence of DTIs. TGT in the presence of different concentrations of two DTIs (dabigatran or 19s) was performed by CAT using the plasma of 5 donors (different for each inhibitor group). The results obtained (mean ± SD, n = 5) are shown in Fig. 2. One can see that at concentrations of up to ~400 nM for dabigatran and ~256 nM for 19s, values of ETP and peak thrombin increase significantly. These parameters begin to decrease with further increase of both inhibitors concentrations (Fig. 2a,b). At the same time the parameters tmax and t-lag increase dramatically with increasing DTI concentrations at all investigated concentrations (Fig. 2c,d).

Parameters of TGT in the presence of DTIs measured upon calibration of the signals using AMC fluorescence. In parallel to CAT, parameters of TGT were determined from the same donor plasma samples in the presence of dabigatran or 19s by the modified method with calibration of the fluorescence signal by AMC fluorescence in each plasma sample. The results obtained are presented in Fig. 3. Like the results obtained with CAT, the values of tmax and t-lag increased dose-dependently with increasing concentrations of thrombin inhibitor (Fig. 3c,d). At the same time, the behaviour of ETP and peak thrombin differed from the results obtained with CAT.

After signal calibration by AMC fluorescence, a very small increase (no more than 2–5% of an initial value) was observed in these parameters at low concentrations of both inhibitors (~10 nM). This increase, however, was insignificant (ANOVA, P > 0.05). The values of ETP and peak thrombin decreased dose-dependently with further increase in dabigatran or thrombin inhibitor 19s concentration (Fig. 3a,b).

Comparison of two modifications of TGT in donors’ plasma. To compare CAT and the proposed modified method, we carried out measuring of thrombin generation in parallel by both of these methods in plasma of 20 donors in the absence of DTI (Fig. 4). The normality of parameters’ distribution has been examined beforehand using the D’Agostino-Pearson test in program MedCalc Statistical Software bvba (version 14.12) (USA, Belgium). All of the parameters in both groups were normal distributed. One-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test was used for statistical analysis to compare two groups,
with a P-value < 0.05 considered to be statistically significant. There were no significant differences for all of the parameters (Fig. 4a,b). The linear regressions were constructed for each parameter measured by both, CAT and our modified TGT method. The coefficients of correlation of these linear regressions were high enough. As the examples, the linear regressions for ETP (Fig. 4c) and t-lag (Fig. 4d) are presented.

Comparison of two modifications of TGT in patients receiving DE. A comparison of the TGT parameters obtained in parallel by both CAT and the proposed modified method was carried out in two patients with a recurrence of multiple myeloma and severe renal failure, who received chemotherapy (patients 1 and 2), and seven patients with knee replacement (patients 3–9). All these patients received DE for the prophylaxis of thrombosis.

Patient 1. Along with chemotherapy (thalidomide 100 mg/day and dexamethasone 40 mg/day), patient received prophylactic dose of DE (110 mg) once per day. Thrombin generation was examined after one course of chemotherapy. The modified method showed that this dose of preparation stably supported ETP in the decreased state compared with normal values determined previously in donors’ plasma (n = 50) (Fig. 5a), and it decreased the initially heightened values of peak thrombin to the lower limit of the reference values (Fig. 5b). Both CAT and the modified method showed similar values for ETP and peak thrombin in the absence of DE (the first and second points in Fig. 5a,b), but these parameters increased in CAT after the administration of the preparation (Fig. 5a,b) because of inhibition of the calibrator (ThrCal) activity. Both methods showed approximately equal prolongation of tmax and t-lag in the presence of DE (Fig. 5c,d).

Patient 2. The state of haemostasis of patient 2 was followed over a long time period. For this time period, patient received 2 courses of chemotherapy, including thalidomide (100 mg/day) and dexamethasone (40 mg/day), for 4 days with 28-day intervals between courses. In the following course, thalidomide was replaced by lenalidomide (5 mg/day). Anticoagulant therapy proceeded during all periods of supervision. Patient received prophylactic dose of DE (110 mg) once per day.
The thrombosis of arteriovenous fistula was observed one day after changing the chemotherapy regimen. The results of the parallel measurements of TGT performed by two different methods are presented in Fig. 6. The first points in all the panels of the figure correspond to the initial values of each parameter before the beginning of chemo- and anticoagulant therapy. After the first course of chemotherapy and the start of DE administration, the modified TGT showed a decrease in the heightened initial values of ETP and peak thrombin to values significantly lower than normal values, and maintained them at these levels (Fig. 6a,b). In the third course of chemotherapy, after switching to lenalidomide, when the patient obtained thrombosis, the values of ETP and peak thrombin determined by the modified method were increased relative to reference values (Fig. 6a,b).

CAT showed increased values of ETP and peak thrombin at the initial time point (without DE), which were similar to the corresponding values determined by the new variant of TGT. However, after DE, the values of these parameters did not decrease; in fact, they increased (Fig. 6a,b) and were maintained at levels higher than normal values during the entire therapeutic period. The appearance of thrombosis did not change ETP and only slightly increased peak thrombin (Fig. 6a,b).

The parameters tmax and t-lag changed equally upon TGT by both methods. They were prolonged after DE administration, but shortened (up to normal or slightly increased values) upon thrombosis detection (Fig. 6c,d).

Patients 3–9. For these patients with knee replacement surgery TT was measured in all of the investigated points (before, as well as 3 and 24 h after surgery) (Fig. 7a). We were able to roughly estimate the concentration of dabigatran in plasma, using the results of the study9 (Fig. 7b). The panels c, d in Fig. 7 show the parameters of the TGT, obtained using our modified method with calibration by AMC (the solid lines), and with the regular CAT method with calibration by ThrCal (the dash lines) in the patients who received DE (220 mg) in the first time (the next morning after operation). ETP (Fig. 7c) and peak thrombin (data not shown) decreased 3 hours after administration of DE if they were determined by the modified method, and then increased again (24 h after the first administration). An increase in dabigatran concentration corresponded to decrease in these parameters.
(Fig. 7b,c). At the same time, these parameters measured by CAT increased 3 hours after receiving DE, and then decreased again after 24 h (Fig. 7c). The parameters tmax (Fig. 7d) and t-lag (data not shown) changed in parallel for both modifications of the TGT as it was expected.

Discussion
The possibility of inhibition of $\alpha_2$MT complex (ThrCal) in the presence of DTIs has been shown in ref. 32 and has been assumed in recent works, where the assessment of the efficiency of the clinical application of DE using TGT has been discussed. However in contrast to plasma of patients receiving DE, plasma in the study32 has not contained DTI (AR-H067637) in the calibration wells, and the authors have observed only a low ETP increase (~10–15%) at low DTI concentrations (<100 nM). That has been explained by incorrect algorithm for calculation of $\alpha_2$MT level in the experimental wells in the presence of a reversible competitive inhibitor. The authors even have concluded that the artificial increase in ETP at low inhibitor concentrations disappears, if the first part of an area under thrombin generation curve (until maximum thrombin concentration in the sample) is used for characterization of the thrombin generation, and therefore, this method may be well suited for a characterization of the thrombin generation in the plasma of patients. However, it is not so. The authors of 32 have not considered the question, that the presence of DTI in the starting plasma of patients should reduce an activity of ThrCal, which has been introduced into this plasma in the calibration wells, and thus should lead to a complete inability to use CAT for the patients' plasma with DTIs. The authors of 32 could not see this effect, because to measure the calibration signal they used the plasma without added thrombin inhibitor. We assumed and demonstrated experimentally that the main reason for the high paradoxical increase of ETP and peak thrombin in CAT in patients receiving DTIs was an inhibition of ThrCal in the calibration wells. It was shown that DTIs decrease the activity of ThrCal both in buffer solution (Fig. 1a,b) and in plasma (Fig. 1c,d). The use of this complex as a thrombin-calibrator in the presence of DTIs results in a decrease of the value of calibration signal (counting on the thrombin activity which is given in an instruction to the used reagent), and therefore in the overvaluation of the parameters ETP and peak thrombin in the presence of the same total signal values (Fig. 2a,b). At the same time, the time parameters of TGT (tmax and t-lag) were prolonged with increased concentrations of inhibitors.
(i.e. they were changed in the expected direction) (Fig. 2c,d). This was observed in a study30 that measured TGT by CAT in patients receiving DE (220 mg/day) for thromboprophylaxis. On the second day after total hip/knee replacement surgery, ETP and peak thrombin in these patients increased approximately two times; at the same time, tmax and t-lag were significantly prolonged. To explain this fact, the authors refer to the work32. However, it is clear that the effect obtained in30 cannot be explained completely by these reasons. This effect is much greater (ETP increases twice) and it is reached at much higher concentrations of inhibitor (corresponding to34, dabigatran concentration in patient plasma after DE administration (150 mg bid or 220 mg once daily can reach up to 184 μg/l (390 nM), but in some cases, this concentration may reach up to 408 μg/l (865 nM)17). The effects observed in our study conform to those observed in30: ETP increases two-fold at a dabigatran concentration of 140 nM and continues to increase with further increases in concentration up to ~800 nM (Fig. 2a).

Similar measurements of the CAT parameters in in vitro experiments were performed in refs 11,24, but in these studies, no increase of ETP and peak thrombin in the presence of dabigatran was observed. This may be because in these experiments, dabigatran also was not added to the calibration wells. Thus, the effect of ETP increase observed in the work32 was different from the effect we observed. These effects could be explained by different reasons. It is clear that signal calibration without the presence of thrombin inhibitor in calibration wells may be used in vitro when different concentrations of thrombin inhibitors (including dabigatran) are added to the plasma during the experiment. However, such an arrangement should be excluded upon the measurement of thrombin generation in patients whose plasma already contains this inhibitor in unknown concentrations. Thus, the proper measurement of the calibration signal for the plasma of each patient is necessary, since the calibration fluorescence signal in CAT depends on both the colour and composition of plasma and on the concentration of present thrombin inhibitor (dabigatran).

Figure 5. Parameters of TGT determined ex vivo in patient 1 using two variations of the method. (a–d) Endogenous thrombin potential (ETP), maximal thrombin concentration in the sample (peak thrombin), time to maximal concentration (tmax), and time to thrombin concentration 10 nM (t-lag) plotted against time. TGT was measured by CAT (○) and by the modified method with a signal calibration by AMC fluorescence (■). The beginnings of chemotherapy and dabigatran etexilate administration are denoted by arrows. Shaded rectangles show the days of chemotherapy. Horizontal lines note the areas of the previously determined reference values for each parameter (mean ± SD, n = 50).
To adapt TGT for the measurement of the influence of DTIs on the coagulation system, we proposed another method for the calibration of a fluorescent signal to calculate the actual AMC concentration in plasma at each time point. The well-determined concentration of AMC (8 μM) was used as standard for these measurements, and the fluorescent signal of 1 μM of AMC was calculated for each specific plasma. In separate experiments, it was shown that the size of this signal does not depend on the concentration of inhibitor in plasma (see Results).

We carried out in vitro comparative research on the TGT parameters in the same plasma samples, in the absence (n = 20), or in the presence (n = 10) of various concentrations of added thrombin inhibitors (dabigatran and 19s) using both methods of calibration. The results showed that all TGT parameters obtained in the same plasma samples with different methods of calibration in the absence of thrombin inhibitors were practically identical (Fig. 4). The coefficients of a linear regression were >0.88 (P < 0.0001). At the same time, unlike ΣAT, when calibrating a signal using the value of AMC fluorescence, ETp and peak thrombin decreased with the increase of thrombin inhibitor concentration in plasma, as expected (Figs 2 and 3). We also observed a very low increase in ETp at low (less than 100 nM) concentrations of inhibitor. This effect was less than 10% and could be explained by the use an improper algorithm for the subtraction of the amidolytic activity of α2MT complex from the full amidolytic activity of the sample, according to32.

To check the efficiency of our modification of signal calibration in TGT in the presence of DTIs, plasma samples of two patients with multiple myeloma receiving chemotherapy were investigated from the beginning of anticoagulant therapy with DE used for thromboprophylaxis. TGT was performed in parallel using two methods: ΣAT (calibration by means of ThrCal) and the modified method (calibration using the fluorescence of a known AMC concentration) (Figs 5 and 6).

After changing the chemotherapy regimen, the thrombosis was fixed in patient 2 (with a background of the same dose of DE) (Fig. 6). ΣAT demonstrated increasing ETp and peak thrombin in both patients during DE
administration. ETP was practically unchanged and peak thrombin increased when thrombosis occurred (Fig. 6). At the same time, the modified method fixed the decrease of ETP and peak thrombin in the presence of DE, and these parameters immediately increased in patient 2 upon thrombosis (Figs 5 and 6). The parameters tmax and t-lag behaved equally with both methods of calibration (Figs 5 and 6) and were not essentially shorter in comparison to normal values in the moment of originated thrombosis (Fig. 6). This indicates that the estimation of the action of DTIs by the TGT parameters tmax and t-lag may be ineffective. This situation can be explained by the fact that sometimes it is difficult to accurately measure tmax and t-lag and that larger variations exist in these parameters in the whole population (CV_{total} ~ 30%) than for ETP and peak thrombin (CV_{total} ~ 15%)^{35,36}. The parameters ETP and peak thrombin could be more convenient for analysis.

All these conclusions concerning different methods of fluorescent signal calibration were also confirmed in seven other patients, who received DE after total knee replacement surgery (Fig. 7). Peak thrombin and ETP in these patients, which were obtained, using the modified TGT method, showed the correlation with thrombin time (and with dabigatran plasma concentration which was roughly estimated using TT).

Thus, our investigation confirms the inhibitory action of DTIs on the activity of ThrCal, as well as the possibility of applying a new method for signal calibration in TGT to measure the efficiency of thrombin generation in plasma of patients receiving DE. However, our study presents limitations that need to be acknowledged. We comprehensively showed the efficacy of our calibration method in an in vitro study, but only 9 patients actually treated with DE were presented. In addition, two of the most informative cases were patients with multiple myeloma and terminal renal failure receiving dialysis, which is known to affect DE levels. We acknowledge that treatment with DE is not recommended in such patients (see, for example ref. 37), but enrollment of these patients in this investigation was approved due to very specific clinical conditions which associated a high risk venous thromboembolism and transient contraindications to heparin or VKAs. We understand that severe renal failure and dialysis can significantly change dabigatran levels, and we were not able to measure these concentrations in this study. However, since we compared both methods in parallel using the same samples, we believe that the influence of this variation is not critical to our conclusions. Thus, our results suggest that this new calibration method is promising, but more extensive testing in different clinical contexts is warranted before it can be potentially incorporated into clinical practice in the future.

Figure 7. Parameters of TGT determined ex vivo, using two variations of the method, in 7 patients, who received DE after knee replacement surgery. The TGT was measured before DE, as well as 3 and 24 h after the first administration of 220 mg DE. (a) Thrombin times of clotting in different time points. (b) The concentrations of dabigatran in plasma of each patient, calculated accordingly the study^9. (c,d) Endogenous thrombin potential (ETP) and time to maximal concentration (tmax), respectively, plotted against time. TGT was measured by CAT (dash lines) and by the modified method with a signal calibration by AMC fluorescence (solid lines). Mean values ± SD (n = 7) are presented.
Materials and Methods

Ethics Statement. This study was approved by the Ethical Committee of the Center for Theoretical Problems of Physicochemical Pharmacology (Permit Number: 21-04-2009)). All methods were carried out in accordance with the approved guidelines. All participants provided written informed consent before blood collection.

Donors and patients. Donors’ blood was collected at the Blood Transfusion Station of the National Research Center for Hematology and was used without identification in *in vitro* experiments.

Nine patients, who received DE for thrombosis prophylaxis, were included in the *ex vivo* investigation.

Two patients (number 1 and 2) with the recurrence of multiple myeloma and the terminal stage of renal failure received courses of chemotherapy by program: thalidomide (100 mg per day) and dexamethasone (40 mg per day). Patient 1 received one course of chemotherapy. In patient 2, thalidomide was replaced by lenalidomide (5 mg per day) after two courses. Because of high rates of renal failure, both patients were subjected to haemodialysis. Unfractionated heparin (5000–7500 IU) was administered during haemodialysis. For the prophylaxis of thrombosis, patients received dabigatran etexilate (110 mg per day) during the time of supervision. DE is not recommended in the case of severe renal failure. However an anticoagulant prophylaxis was needed since these patients received chemotherapy with thalidomide or lenalidomide combined with dexamethasone. But warfarin and heparins could not be used in these specific patients, therefore it was necessary to test the other anticoagulants. Blood for haemostasis analysis by TGT (in 2 modifications) was collected before haemodialysis into vacuum tubes (Vacuette) with 3.8% (0.129 M) sodium citrate at a blood/anticoagulant ratio of 9/1. Platelet poor plasma (PPP) for tests was prepared by centrifuging blood for 15 min at 1600 g. Clinically apparent thrombosis of arteriovenous fistula was recorded one day after changing the course of chemotherapy in patient 2.

Seven other patients (numbers 3–9) were after knee replacement surgery and received DE in accordance with the currently used guidelines. These patients were investigated before DE, as well as 3 and 24 h after the first dose of DE (220 mg), which was obtained 24 h after knee replacement surgery. The platelet free plasma (PPP) was used for TGT, obtained by double centrifugation (1600 g × 15 min, and then 10000 g × 5 min). Thrombin time in the samples of these patients was measured using Stago STA Compact Coagulation Analyzer (Diagnostica Stago, USA) with reagents kit of Renam (Moscow, Russia).

Reagents. The thrombin-specific chromogenic substrate Tosyl-Gly-Pro-Arg-p-nitroanilide (Chromozym-TH) was purchased from Sigma (USA).

For the thrombin generation test, the following reagents were used: thrombin-specific fluorogenic substrate Z-Gly-Gly-Arg-AMC (Bachem, Switzerland); 7-amino-4-methylcoumarin, CaCl2, dimethyl sulfoxide (DMSO), and NaCl (Sigma-Aldrich, USA); thromboplastin (Renam, Russia); phosphatidylserine (from pig brain) and phosphatidylcholine (from egg yolk) produced by Avanti Polar Lipids Inc. (USA); and 4-(2-hydroxyethyl)-1-piperazine-2-ethanosulphonic acid (HEPES, Fisher Biotech, USA).

The calibrator for the determination of thrombin activity in the CAT test (ThrCal) was purchased from Thrombinoscope BV (the Netherlands) through Laborama (Russia).

Dabigatran (BIBR 953) was obtained from Selleckchem.com. HC-JOC-019s (C22H10S2O-C8H4(CH2)3-O-(CH2)2-N-C5H4(NH3)) was synthesized at the Institute of Organic Chemistry of Russian Academy of Sciences (Russia)33. Pradaxa (dabigatran etexilate) (capsules 110 mg) was from Boehringer Ingelheim (Germany).

Influence of DTIs (dabigatran and 19 s) on ThrCal activity in a buffer system. The activity of ThrCal (measured as units of thrombin activity) was determined from the rate of the hydrolysis of Chromozym-TH by ThrCal in the presence of different concentrations of DTI (dabigatran or 19 s).

Plate wells were filled with 171 μl of buffer A (20 mM HEPES (pH 8.0), 140 mM NaCl, containing 0.1% polyethylene glycol (molecular weight 6000 Da). Thereafter, 4 μl of substrate was added to each well (final concentration 100 μM), followed by 5 μl of the solution of the thrombin inhibitor in DMSO (to a final concentration that was varied) and 20 μl of ThrCal (final concentration 0.73 nM). The hydrolysis rate was monitored spectrophotometrically at 405 nm (absorption maximum of the reaction product—p-nitroaniline) using Appliskan Multimode Microplate Reader (Thermo Scientific, Finland).

The initial hydrolysis rate was determined as the slope for the linear portion of the kinetic curve over the first 10–20 min of measurement. The reaction rate in the absence of inhibitor but with addition of the corresponding concentration of DMSO was taken as 100%. The inhibitory effect was expressed as the percentage reduction of the initial hydrolysis rate. Each result is the mean of two parallel determinations.

Thrombin generation assay. The kinetics of thrombin generation in plasma was monitored using the hydrolysis rate of the slow fluorogenic substrate Z-Gly-Gly-Arg-AMC by thrombin being formed during clotting. This technique is based on the work of H.C. Hemker et al.52. Two modifications of this method were used, which differed only in the method of fluorescent signal calibration: by using ThrCal (CAT) or by signal of fluorescence of a well-known AMC concentration. The following parameters of the TGT were measured in each case: ETP, peak thrombin, tmax and t-lag.

Measurements were taken as follows. PPP was placed in the wells of a 96-well flat-bottom microtiter plate (80 μl/well). Thereafter, 20 μl of the fluorogenic substrate solution was added into each well, along with 5 μl of the thrombin inhibitor solution to be tested in different concentrations. In the wells without inhibitor, 5 μl of the solvent (DMSO) was added. The samples were incubated at 37 °C for 3–5 min, and thrombin generation was triggered with 20 μl of activator. Thromboplastin solution in buffer A, containing an additional 100 mM of CaCl2 and 25 μM of phospholipid suspension (20% of phosphatidylserine: 80% of phosphatidylcholine) was used as an activator of coagulation. Final concentrations of reagents in each sample were as follows: substrate, 400 μM; tissue factor, 5 pM; supplemented CaCl2, 16 mM; and phospholipids, 4 μM. Activator was added to all the well
Calibrated automated thrombogram (CAT). The thrombin generation assay by CAT was performed strictly as described previously by Hemker et al. The signal was calibrated by special thrombin calibrator, which represents α2MT complex (ThrCal). Separate calibration wells were used to determine the concentrations of active thrombin in the sample at each time point. They contained 80 μl of investigated plasma, 20 μl of fluorogenic substrate solution (final concentration 400 μM), additional CaCl2 (final concentration 16 mM), 20 μl of ThrCal with a final activity corresponding to the activity of 116.8 nM thrombin (according to specifications), and 5 μl of thrombin inhibitor solution in DMSO (in corresponding concentrations). Fluorescence signals in the experimental wells were normalized by the signal in the calibration well, thus allowing the calculation of thrombin concentration in the sample at each time point (taking into account an "inner filter" effect caused by changing AMC concentrations in the sample, and changes in the hydrolysis rate caused by substrate consumption during the reaction).

A new modification of the thrombin generation test. For the calibration of the fluorescence signal, two types of wells without clotting plasma were prepared. The first type contained 20 μl of buffer A instead of the activator to obtain the background plasma fluorescence level. The second (calibration wells) contained 10 μl of AMC solution in DMSO and 10 μl of buffer A instead of the activator. The final AMC concentration in these wells was 8 μM.

The background fluorescence was subtracted from the fluorescence signal in all of the wells. The value of fluorescence corresponding to 1 μM of AMC was recognized as the calibration value.

For calculation of a thrombin generation curve it is necessary to take into account:

(a) Nonlinearity of fluorescence intensity dependence on AMC concentration due to "inner filter" effect;
(b) Consumption of the substrate in course of the reaction;
(c) Contribution of amidolytic activity of α2MT in the total AMC concentration and, respectively, in measured fluorescence.

A more detailed description of the main steps of calculating the thrombin generation curve is presented below.

Determination of the dependence of AMC fluorescence on AMC concentration in the plasma (calculation of the "inner filter" effect). A calibration curve was constructed by measurement of the AMC fluorescence in plasma in the presence of different AMC concentrations. We consider, that the concentrations of AMC and a substrate are equal to 0, and 400 μM, respectively, when the thrombin generation in the experimental wells begins, but then the substrate concentration gradually decreases and AMC, respectively, increases. Therefore, our calibration was performed in conditions of a constant sum of concentrations of AMC and the substrate (400 μM) in each point of the curve. The total volume of each sample was equal to 120 μl (80 μl plasma + 20 μl of the substrate solution (of different concentrations) + 10 μl of AMC solution in DMSO (in different concentrations) + 10 μl of buffer A).

The obtained curve was approximated by a function (1):

\[ I_{\text{exp}}(m) = I_{\text{exp}}(m) - I_{\text{b}(m)} = I_0 \cdot (1 - e^{-k[AMC]}) \]

where \( I_{\text{exp}}(m) \) is a total measured fluorescence at certain [AMC] concentration; \( I_{\text{exp}}\) = fluorescence in the experimental wells after subtraction of the measured background plasma fluorescence \( I_{\text{b}(m)} \); and \( k \) – the coefficient of approximation.

For fluorescence in the calibration wells the following equation is correct:

\[ I_{\text{cal}}(m) = I_{\text{cal}}(m) - I_{\text{b}(m)} = I_0 \cdot (1 - e^{-Ak}) \]

where \( I_{\text{cal}}(m) \) is the total measured fluorescence in the calibration wells; \( I_{\text{cal}} \) = fluorescence in the calibration wells without a background plasma fluorescence, and \( A \) – the AMC concentration in the calibration wells.

The real concentration of AMC in each time point may be calculated from equations (1) and (2) (at given coefficient \( k \)):

\[ [\text{AMC}] = - \frac{(1/k) \cdot \ln [1 - I_{\text{exp}} \cdot (1-e^{-Ak})/I_{\text{cal}}]}{I_{\text{exp}} - I_{\text{b}(m)}} \]

The calibration curves measured in 13 plasmas of healthy donors are presented in Fig. 8a. It was shown that the shape of the each curve may be described by the function (1). The averaged calibration curve (mean ± SD, n = 13) and its approximation using this function is presented in Fig. 8b. The mean value of \( k \) may be obtained by averaging out all the individual \( k \), calculated for each calibration curve (Fig. 8a), or it may be estimated from average curve (Fig. 8b). These values were similar enough (Fig. 8c), and were equal to 0.00374 ± 0.00044 or to 0.00366 ± 0.00032 μM⁻¹, respectively.
Despite the fact that the values of the approximation coefficients \( k \) in different plasma may vary (CV\text{total} for \( k \sim 11.8\% \)), it does not lead to significant differences in the results calculated using equation (3) in the certain plasma. The relative experimental error (CV\text{error}) for \( k \) determination was calculated in separate experiments with pool of 5 donors' plasma. The similar calibration curves were measured in 5 independent runs with this plasma pool. The mean CV\text{error} was equal to \( \sim 8\% \). The inter-individual coefficient of variation (CV\text{ii}) for \( k \) was calculated according to35 and it appeared to be equal to \( \sim 8.7\% \). The calculated AMC concentration, which may be obtained using the minimal and maximal possible values of \( k \) (in SD interval) does not differ by more than 5–6% for the highest really observed fluorescence intensity (\( \sim 90000–100000 \text{ arb. un.} \)) (Fig. 8d). This situation corresponds to the value of a ratio \( I_{\text{exp}}/I_{\text{cal}} \) equal to \( \sim 15 \). Therefore, then we used the average \( k \) value for all the investigated samples.

It should be noted that the coefficients \( k \) can be accurately calculated for the each plasma at the proviso that two calibration AMC concentrations are used. The simple equation (4) is correct, if these concentrations differ in magnitude by 2 times.

![Equation (4)](equation.png)

where \( I_{\text{cal}} \) and \( I_{\text{cal}} \) - intensity of fluorescence (without a background plasma fluorescence) in the calibration wells with AMC concentration of \( A \) and \( 2A \), respectively.

However in this study the calculation of the “inner filter” effect was conducted using the average value of \( k \) (i.e., with an accuracy of 5–6%).

**Calculation of a total thrombin activity present in plasma.** Knowing the rate of accumulation of a product of substrate cleavage in a sample at each time point and considering that the reactions of hydrolysis for this substrate...
under the action of thrombin and $\alpha_2$MT complex follow Michaelis-Menten kinetics, it is possible to calculate the appropriate conditional total activity of thrombin in plasma from the following equation (5):

$$\frac{d[AMC]}{dt} = k_{cat1} \cdot [T] \cdot [S]/(K_M + [S]) + k_{cat2} \cdot [\alpha_2MT] \cdot [S]/(K_M + [S]).$$

$$= k_{cat1} \cdot [T]_{total} \cdot [S]/(K_M + [S]),$$

(5)

where $[T]_{total}$- the conditional total concentration of thrombin in the sample, which represents the sum of concentrations of the free enzymes and the enzyme-substrate complexes. It may be described by formula (6):

$$[T]_{total} = [T] + k_{cat2} \cdot [\alpha_2MT]/k_{cat1},$$

(6)

where $[T]$ and $[\alpha_2MT]$ are the concentrations of the free thrombin +TS complex, and complex of thrombin with $\alpha_2$-macroglobulin +$\alpha_2$MTS complex, respectively; $K_M$, $k_{cat1}$ and $k_{cat2}$ are the kinetic constants of thrombin and $\alpha_2$MT complex in relation to the fluorogenic substrate (the given kinetic constants for thrombin were previously determined as follows: $K_M = 156 \mu\text{M}$, $k_{cat1} = 46 \text{ min}^{-1}$, and the $K_M$ value for $\alpha_2$MT was approximately equal to $K_M$ for thrombin ($160 \mu\text{M}$); $[S]$ is the concentration of the substrate in a sample in the corresponding time point. Since the sum of $[TS]$ and $[\alpha_2MTS]$ is much lesser than $S_0$, the $[S]$ value may be calculated from the initial substrate concentration ($S_0$) and current $[AMC]$ concentration by equation (7):

$$[S] = S_0 - [AMC];$$

(7)

From (5) and (7) it may be finally obtained:

$$[T]_{total} = (K_M + S_0 - [AMC])/(k_{cat1} \cdot (S_0 - [AMC])) \cdot d[AMC]/dt.$$  

(8)

It should be noted that the equation (8) makes it possible to calculate the sum of the concentrations of free enzymes and the enzyme-substrate complexes. The use of this equation allows us to compare the results obtained with our modified method and the CAT, which also calculates this parameter. If it is necessary to calculate the concentrations of the free enzymes, the resulting value $[T]_{total}$ should be multiplied by a coefficient $K_M/(K_M + S)$.

**Calculation of $\alpha$MT contribution in the conditional total thrombin activity.** This calculation did not depend on a mode of calibration of the fluorescent signal, and was carried out absolutely the same way as it has been described previously in the study39. We supposed that binding $\alpha_2$-macroglobulin ($\alpha_2$MG) with thrombin is irreversible and that the rate of $\alpha_2$MT complex accumulation is proportional to the concentration of thrombin in each time point:

$$d[\alpha_2MT]/dt = k_3 \cdot [\alpha_2MG] \cdot [T].$$

(9)

It may be supposed that $[\alpha_2MG] \approx$ constant, since $[\alpha_2MT]$ is much lesser than initial $[\alpha_2MG]$ concentration. Turning to the finite differences in the equations (9) and (6) we obtain:

$$\Delta[\alpha_2MT]_{(t)} = k_3 \cdot [\alpha_2MG] \cdot [T]_{(t-\Delta t)} \cdot \Delta t,$$

(10)

and

$$\Delta[T]_{total(t)} = \Delta[T]_{(t)} + k_{cat2} \cdot \Delta[\alpha_2MT]_{(t)}/k_{cat1}$$

(11)

where indexes $(t - \Delta t)$ and $(t)$ correspond to the time moments $(t - \Delta t)$ and $t$, respectively.

Therefore, finally the equation for increment of the sum concentration of free thrombin plus thrombin-substrate complex on each time step may be obtained:

$$\Delta[T]_{(t)} = \Delta[T]_{total(t)} - \alpha \cdot [T]_{(t-\Delta t)} \cdot \Delta t,$$

(12)

where

$$\alpha = k_{cat2} \cdot k_3 \cdot [\alpha_2MG]/k_{cat1}.$$  

(13)

The value of $\alpha$ is selected for each plasma sample individually, based on the condition that at the final part of the thrombin generation curve, when the rate of the product accumulation goes out to the stationary level, the $[T] = 0$, and the cleavage of the substrate is completely determined only by $\alpha_2$MT complex. The special template was constructed in the Origin 6.0 (Microcal Software, USA) for selection of $\alpha$ value using spreadsheet40.

**References**

1. Eisert, W. G. *et al.* Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. *Arterioscler Thromb Vasc Biol.* 30, 1885–1889 (2010).

2. Baetz, B. E. & Spinler, S. A. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. *Pharmacotherapy* 28, 1354–1373 (2008).

3. Stangier, J. *et al.* Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. *J Clin Pharmacol* 45, 555–563 (2005).

4. Trocínz, I. F., Tillmann, C., Liesenfeld, K. H., Schäfer, H. G. & Stangier, J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. *J Clin Pharmacol* 47, 371–382 (2007).

5. Van Es, N. & Buller, H. R. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations. *Hematology Am Soc Hematol Educ Program* 2015, 125–131 (2015).
6. Schumlan, S. et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 114, 150–157 (2015).

7. Wienen, W., Stassen, J.-M., Priepke, H., Ries, U. I. & Hauel, N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98, 155–162 (2007).

8. Kyrakou, E. et al. Laboratory assessment of the anticoagulant activity of dabigatran. Clin Appl Thromb Hemost 21, 434–445 (2015).

9. Stangier, J., Rathgen, K., Stähle, H., Gansser, D. & Roth, W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64, 292–303 (2007).

10. Stangier, J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor Dabigatran Eteinilate. Clin Pharmacokinet 47, 285–295 (2008).

11. Douxfils, J. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 107, 985–997 (2012).

12. Spannagl, M. et al. Dabigatran therapy—perioperative management and interpretation of coagulation tests. Hämostaseologie 32, 294–305 (2012).

13. Ten Cate, H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J 11, 8 (2013).

14. Ten Cate, H. Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb Haemost 107, 803–805 (2012).

15. Hapgood, G., Butler, J., Malan, E., Chunilal, S. & Tran, H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 110, 308–313 (2013).

16. Montaruli, B. et al. Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man. Blood Coagul Fibrinolysis 26, 225–229 (2015).

17. Chin, P. K. et al. Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol 78, 630–638 (2014).

18. Dietrich, K., Stang, L., van Ryn, J. & Mitchell, L. G. Assessing the anticoagulant effect of dabigatran in children: An in vitro study. Thromb Res 135, 630–635 (2015).

19. Dager, W. E., Gosselin, R. C., Kitchen, S. & Dwyer, D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, and thrombin time: a multicenter, in vitro study. Ann Pharmacother 46, 1627–1636 (2012).

20. Lippl, G. & Favoloro, E. J. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs); is there consensus? Clin Chem Lab Med 53, 185–197 (2015).

21. Van Ryn, J., Grottker, O. & Spronk, H. Measurement of dabigatran in standardized clinical trials, whole blood viscoelastic coagulation, and thrombin generation assays. Clin Lab Med 34, 479–501 (2014).

22. Chin, P., Wright, D., Patterson, D., Doogue, M. & Regg, E. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol 78, 599–609 (2014).

23. Van Ryn, J. et al. Dabigatran etexilate—a novel, reversible, direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103, 1116–1127 (2010).

24. Dinkelaar, J., Patiwael, S., Harenberg, J., Leyte, A. & Brinkman, H. J. M. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med 52, 1613–1623 (2014).

25. Hemker, H. C. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 32, 249–253 (2002).

26. Sharrock, N. E. et al. Changes in circulatory indices of thrombosis and fibrinolysis during total knee arthroplasty performed under tourniquet. J Arthroplasty 10, 523–528 (1995).

27. Al Dieri, R., Albani, S., Beguin, S. & Hemker, H. C. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. Thromb Haemost 92, 1395–1401 (2004).

28. Al Dieri, R., Albani, S., Beguin, S. & Hemker, H. C. Fixed dosage of low-molecular-weight heparin causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 4, 83–89 (2006).

29. Gatt, A. et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 100, 350–355 (2008).

30. Green, L. et al. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters. Thromb Res 130, 775–779 (2012).

31. Helin, T. A. et al. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples. Thromb Res 135, 154–160 (2015).

32. Wagenwoord, R. J., Deinum, J., Elg, M. & Hemker, H. C. The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin. J Thromb Haemost 8, 1281–1289 (2010).

33. Sinauridze, E. I. et al. New Synthetic Thrombin Inhibitors: Molecular Design and Experimental Verification. PLoS ONE 6, e19969 (2011).

34. Wong, P. C., White, A. & Luettingen, J. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. Hospital Practice 41, 19–25 (2013).

35. Bloemen, S., Hemker, H. C. & Al Dieri, R. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica 98, 549–554 (2013).

36. Hemker, H. C. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33, 4–15 (2003).

37. Ragan I. on behalf of Lancashire and Cumbria Health Economy New Medicines and Treatments Group. Guidance for prescribing of Dabigatran (Pradaxa) Rivaroxaban (Xarelto) and Apixaban (Eligix) in Patients with Non-Valvular, A. F., 2012. Available at: http://www.cumbria.nhs.uk/ProfessionalZone/MedicinesManagement/Guidelines/Prescribing-Guidance-for-NOACs.pdf (Accessed April 28, 2016).

38. Tarandovskiy, I. D., Artemenko, E. O., Panteleev, M. A., Sinauridze, E. I. & Ataullakhanov, F. I. Antiplatelet agents can promote two-peaked thrombin generation in platelet rich plasma: mechanism and possible applications. PLoS ONE 8, e56888 (2013).

39. Hemker, H. C. & Kremers, R. Data management in thrombin generation. Thromb Res. 131, 3–11 (2013).

40. Sinauridze, E. I. et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 97, 425–434 (2007).

Acknowledgements
The authors thank Ph.D. Natalia Dashkevich (Hematological Corporation “HemaCore” LLC, Moscow) for her kind help with the plasma samples of patients after knee replacement surgery. The work was supported by Russian Science Foundation grant N 16-14-00224.

Author Contributions
E.I.S. conceived the study, analysed results, wrote and approved the manuscript; I.V.G. performed experiments, analysed the results, and wrote the manuscript; I.G.R., A.I.B., D.B.A. and R.A.O. provided medical treatment of the patients and the samples collection; E.N.L. performed experiments and discussed the results, F.I.A. discussed the results.
Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Gribkova, I. V. et al. The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency. Sci. Rep. 6, 29242; doi: 10.1038/srep29242 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/